{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:51:32Z","timestamp":1769853092584,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012943","name":"INRS University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012943","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fonds de Recherche en Sant\u00e9 du Qu\u00e9bec","award":["#32622"],"award-info":[{"award-number":["#32622"]}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["#34846"],"award-info":[{"award-number":["#34846"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012618","name":"Armand-Frappier Foundation of INRS University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012618","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejmech.2017.03.029","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T19:45:10Z","timestamp":1489866310000},"page":"282-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in\u00a0vitro cytotoxicity against cancer cells and a lower in\u00a0vivo toxicity in zebrafish embryos than clinically approved cis-platin"],"prefix":"10.1016","volume":"132","author":[{"given":"MohammadMehdi","family":"Haghdoost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golara","family":"Golbaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"L\u00e9tourneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunmoogum A.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-6353","authenticated-orcid":false,"given":"Annie","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.03.029_bib1","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1021\/bm400104b","article-title":"Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity","volume":"14","author":"Mangiapia","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejmech.2017.03.029_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cbpa.2007.11.013","article-title":"New trends for metal complexes with anticancer activity","volume":"12","author":"Bruijnincx","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2017.03.029_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.bjc.6600290","article-title":"In\u00a0vitro and in\u00a0vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer","volume":"86","author":"Aird","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.03.029_bib4","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","article-title":"KP1019, a new redox-active anticancer agent \u2013 preclinical development and results of a clinical phase I study in tumor patients","volume":"5","author":"Hartinger","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2017.03.029_bib5","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A\u00a0phase I and pharmacological study with imidazolium-trans-dmso-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.029_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejmech.2017.03.029_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drup.2006.05.002","article-title":"DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity","volume":"9","author":"Brabec","year":"2006","journal-title":"Drug resist. Update"},{"key":"10.1016\/j.ejmech.2017.03.029_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00280-004-0773-6","article-title":"Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines","volume":"54","author":"Pluim","year":"2004","journal-title":"Cancer chemoth. Pharm."},{"key":"10.1016\/j.ejmech.2017.03.029_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejmech.2014.08.071","article-title":"Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin","volume":"86","author":"Zhang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib10","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1021\/jm301376a","article-title":"Structure-activity relationships of targeted RuII(\u03b76-p-cymene) anticancer complexes with flavonol-derived ligands","volume":"55","author":"Kurzwernhart","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib11","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1039\/C2DT32206D","article-title":"3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands","volume":"42","author":"Kurzwernhart","year":"2013","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib12","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1021\/ic050194p","article-title":"Structure-function relationships within keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]","volume":"44","author":"Mura","year":"2005","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/om800899e","article-title":"Influence of structural variation on the anticancer activity of RAPTA-type complexes: ptn versus pta","volume":"28","author":"Renfrew","year":"2009","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib14","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1039\/c0dt01807d","article-title":"1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity","volume":"40","author":"Bratsos","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1021\/om800207t","article-title":"Influence of the spacer length on the in\u00a0vitro anticancer activity of dinuclear ruthenium-arene compounds","volume":"27","author":"Mendoza-Ferri","year":"2008","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib16","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/om900359j","article-title":"Synthesis, molecular structure, and anticancer activity of cationic arene ruthenium metallarectangles","volume":"28","author":"Mattsson","year":"2009","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib17","doi-asserted-by":"crossref","first-page":"15602","DOI":"10.1039\/C5DT02446C","article-title":"Labile ruthenium(II) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation","volume":"44","author":"Huang","year":"2015","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib18","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1039\/C5DT00169B","article-title":"Lipophilicity-dependent ruthenium N-heterocyclic carbene complexes as potential anticancer agents","volume":"44","author":"Lv","year":"2015","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib19","doi-asserted-by":"crossref","first-page":"11274","DOI":"10.1021\/ic501865h","article-title":"Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands","volume":"53","author":"Martinez-Alonso","year":"2014","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib20","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1021\/ic049479c","article-title":"Tuning of redox potentials for the design of ruthenium anticancer drugs - an electrochemical study of [trans-RuCl4L(dmso)]- and [trans-Rucl4L2]- complexes, where L= imidazole, 1,2,4-triazole, Indazole","volume":"43","author":"Reisner","year":"2004","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib21","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/jm061081y","volume":"50","author":"Groessl","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib22","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1021\/acs.jmedchem.5b00288","article-title":"Structure-related mode-of-action differences of anticancer organoruthenium complexes with \u03b2-diketonates","volume":"58","author":"Sersen","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib23","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1039\/c0dt01816c","article-title":"Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs","volume":"40","author":"Bergamo","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.trac.2016.04.015","article-title":"Role of metallomic strategies in developing ruthenium anticancer drugs","volume":"80","author":"Timerbaev","year":"2016","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib25","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/ejic.201402205","article-title":"Substitution-modulated anticancer activity of half-sandwich ruthenium(II) complexes with heterocyclic ancillary ligands","volume":"2014","author":"Mitra","year":"2014","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib26","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1021\/jm060596m","article-title":"Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands","volume":"49","author":"Habtemariam","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/jm3017442","article-title":"The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway","volume":"56","author":"Romero-Canelon","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00775-008-0460-x","article-title":"Ruthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds?","volume":"14","author":"Corral","year":"2009","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jinorgbio.2007.07.035","article-title":"Synthesis, antitumor activity and structure-activity relationships of a series of Ru(II) complexes","volume":"102","author":"Liu","year":"2008","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/chem.201404922","article-title":"Comparison between polypyridyl and cyclometalated ruthenium(II) complexes: anticancer activities against 2D and 3D cancer models","volume":"21","author":"Huang","year":"2015","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2017.03.029_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1515\/medr-2015-0001","article-title":"Expanding on the structural diversity of flavone-derived rutheniumII(\u03b76-arene) anticancer agents","volume":"1","author":"Kubanik","year":"2015","journal-title":"Metallodrugs"},{"key":"10.1016\/j.ejmech.2017.03.029_bib32","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1038\/ncomms4462","article-title":"Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity","volume":"5","author":"Adhireksan","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2017.03.029_bib33","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s11176-005-0512-7","article-title":"Quantitative structure-property relationship: XXIII. Solubility of oxygen in organic solvents","volume":"75","author":"Golovanov","year":"2005","journal-title":"Russ. J. Gen. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell Line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.03.029_bib35","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2017.03.029_bib36","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1021\/ic061008y","article-title":"Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis","volume":"45","author":"Ang","year":"2006","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib37","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1021\/ic061460h","article-title":"Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity","volume":"45","author":"Dougan","year":"2006","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib38","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1002\/chem.200304724","article-title":"Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts","volume":"9","author":"Wang","year":"2003","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2017.03.029_bib39","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jinorgbio.2008.05.004","article-title":"Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(\u03b76-p-cymene)Cl2(pta)]","volume":"102","author":"Scolaro","year":"2008","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib40","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1021\/om700364s","article-title":"pKa estimation of ruthenium(II)-arene pta complexes and their hydrolysis products via a DFT\/continuum electrostatics approach","volume":"26","author":"Gossens","year":"2007","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jinorgbio.2007.11.018","article-title":"CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP","volume":"102","author":"Groessl","year":"2008","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1040-8428(01)00224-4","article-title":"Titanium complexes in cancer treatment","volume":"42","author":"Melendez","year":"2002","journal-title":"Cri. Rev. Oncol. Hemat"},{"key":"10.1016\/j.ejmech.2017.03.029_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/ja027719m","article-title":"Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms","volume":"125","author":"Chen","year":"2003","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2017.03.029_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0009-2797(80)90122-2","article-title":"Kinetic analysis of the in\u00a0vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA","volume":"30","author":"Johnson","year":"1980","journal-title":"Chem.-Biol. Interact."},{"key":"10.1016\/j.ejmech.2017.03.029_bib45","first-page":"1365","article-title":"Glossary of terms used in photochemistry","volume":"79","author":"Braslavsky","year":"2009","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib46","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1021\/om900483t","article-title":"From pyrone to thiopyrone ligands\u2212rendering maltol-derived ruthenium(II)\u2212arene complexes that are anticancer active in\u00a0vitro","volume":"28","author":"Kandioller","year":"2009","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib47","first-page":"1972","article-title":"Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA","volume":"46","author":"Knox","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.029_bib48","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1021\/ic400816g","article-title":"Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes","volume":"52","author":"Pichler","year":"2013","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jinorgbio.2003.08.014","article-title":"Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)","volume":"98","author":"Ghezzi","year":"2004","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/jm001080k","article-title":"Calculation of the hydrophobicity of platinum drugs","volume":"44","author":"Platts","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib51","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1021\/jm901556u","article-title":"Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells","volume":"53","author":"van Rijt","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10822-005-8694-y","article-title":"Virtual computational chemistry laboratory-design and description","volume":"19","author":"Tetko","year":"2005","journal-title":"J.\u00a0Comput.-Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.03.029_bib53","series-title":"Virtual Computational Chemistry Laboratory","author":"VCCLAB","year":"2005"},{"key":"10.1016\/j.ejmech.2017.03.029_bib54","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1021\/jm3002857","article-title":"In\u00a0vitro anticancer activity of cis-diammineplatinum(II) complexes with \u03b2-diketonate leaving group ligands","volume":"55","author":"Wilson","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jinorgbio.2013.07.010","article-title":"New steroidal 7-azaindole platinum(II) antitumor complexes","volume":"128","author":"Zamora","year":"2013","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ica.2014.07.030","article-title":"Design, synthesis and comparative cytotoxic investigation of platinum(II) complexes with some derivatives of 5-methyl-5-(4-pyridyl)hydantoin","volume":"423","author":"Bakalova","year":"2014","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.ejmech.2017.03.029_bib57","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1039\/C5CS00134J","article-title":"Linking the future of anticancer metal-complexes to the therapy of tumour metastases","volume":"44","author":"Bergamo","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2017.03.029_bib58","first-page":"e51046","article-title":"In\u00a0vitro cell migration and invasion assays","author":"Justus","year":"2014","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.ejmech.2017.03.029_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In\u00a0vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in\u00a0vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2017.03.029_bib60","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A\u00a0phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.029_bib61","unstructured":"E. Alessio, Thirty years of the drug candidate NAMI-A and the myths in the field of ruthenium anticancer compounds: a personal perspective, Eur. J. Inorg. Chem. [Online early access]. 10.1002\/ejic.201600986."},{"key":"10.1016\/j.ejmech.2017.03.029_bib62","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1039\/C4DT01356E","article-title":"NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels","volume":"43","author":"Pillozzi","year":"2014","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib63","series-title":"Medicinal Chemistry: an Introduction","author":"Thomas","year":"2000"},{"key":"10.1016\/j.ejmech.2017.03.029_bib64","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd4627","article-title":"Zebrafish as tools for drug discovery","volume":"14","author":"MacRae","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2017.03.029_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10529-008-9868-1","article-title":"Significance of the zebrafish model in the discovery of bioactive molecules from nature","volume":"31","author":"Mandrekar","year":"2008","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ejmech.2017.03.029_bib66","first-page":"62","article-title":"The state of the art of the zebrafish model for toxicology and toxicologic pathology research-advantages and current limitations","volume":"31","author":"Spitsbergen","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejmech.2017.03.029_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acs.organomet.5b00820","article-title":"Arene ruthenium(II) complexes as low-toxicity inhibitor against the proliferation, migration, and invasion of MDA-MB-231 cells through binding and stabilizing c-myc G-quadruplex DNA","volume":"35","author":"Wu","year":"2016","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2017.03.029_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbi.2009.08.005","article-title":"A\u00a0novel phenotype-based approach for systematically screening antiproliferation metallodrugs","volume":"182","author":"Wang","year":"2009","journal-title":"Chemico-biol. Interact."},{"key":"10.1016\/j.ejmech.2017.03.029_bib69","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/etc.5620061009","article-title":"Endpoints for responses of fish to chronic toxic exposures","volume":"6","author":"Suter","year":"1987","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib70","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1021\/jm5017686","article-title":"Synthesis and evaluation of series of diazine-bridged dinuclear platinum(II) complexes through in\u00a0vitro toxicity and molecular modeling: correlation between structure and activity of Pt(II) complexes","volume":"58","author":"Senerovic","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.029_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.chemosphere.2009.08.033","article-title":"Uptake of platinum by zebrafish (Danio Rerio) and ramshorn snail (Marisa Cornuarietis) and resulting effects on early embryogenesis","volume":"77","author":"Osterauer","year":"2009","journal-title":"Chemosphere"},{"key":"10.1016\/j.ejmech.2017.03.029_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1039\/dt9740000233","article-title":"Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride","author":"Bennett","year":"1974","journal-title":"J.\u00a0Chem. Soc. Dalton Trans."},{"key":"10.1016\/j.ejmech.2017.03.029_bib73","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ma402078d","article-title":"Superior chemotherapeutic benefits from the ruthenium-based anti-metastatic drug NAMI-A through conjugation to polymeric micelles","volume":"47","author":"Blunden","year":"2014","journal-title":"Macromolecules"},{"key":"10.1016\/j.ejmech.2017.03.029_bib74","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2017.03.029_bib75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A\u00a0short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr. Sect. A"},{"key":"10.1016\/j.ejmech.2017.03.029_bib76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT - integrated space-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. A"},{"key":"10.1016\/j.ejmech.2017.03.029_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/aja.1002030302","article-title":"Stages of embryonic development of the zebrafish","volume":"203","author":"Kimmel","year":"1995","journal-title":"Dev. Dynam."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417301873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417301873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T21:59:26Z","timestamp":1655675966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417301873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":77,"alternative-id":["S0223523417301873"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.029","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in\u00a0vitro cytotoxicity against cancer cells and a lower in\u00a0vivo toxicity in zebrafish embryos than clinically approved cis-platin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}